Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „dupilumab“
Suchtreffer
Begriffe & Kennungen
Dupixent · 4.8 · Approximately 16 % of adolescent patients with atopic dermatitis who received dupilumab 300 mg or 200 mg Q2W f
Eintrag öffnenDupixent · 4.8 · Approximately 16 % of adolescent patients with atopic dermatitis who received dupilumab 300 mg or 200 mg Q2W f
Eintrag öffnenDupixent · 4.8 · Approximately 4.7% of adult patients with CSU who received dupilumab 300 mg Q2W and adolescent patients with C
Eintrag öffnenDupixent · 4.8 · Approximately 5 % of patients with atopic dermatitis, asthma, or CRSwNP who received dupilumab 300 mg Q2W for
Eintrag öffnenDupixent · 4.8 · Approximately 5 % of patients with atopic dermatitis, asthma, or CRSwNP who received dupilumab 300 mg Q2W for
Eintrag öffnenDupixent · 4.8 · Approximately 8% of patients with COPD who received dupilumab 300 mg Q2W for 52 weeks developed antibodies to
Eintrag öffnenDupixent · 4.8 · Approximately 8% of patients with COPD who received dupilumab 300 mg Q2W for 52 weeks developed antibodies to
Eintrag öffnenDupixent · 4.8 · Approximately 9 % of patients with asthma who received dupilumab 200 mg Q2W for 52 weeks developed antibodies
Eintrag öffnenDupixent · 4.8 · Approximately 9 % of patients with asthma who received dupilumab 200 mg Q2W for 52 weeks developed antibodies
Eintrag öffnenDupixent · 4.8 · Atopic Hand and Foot Dermatitis The safety of dupilumab was assessed in 27 paediatric patients 12 to 17 years
Eintrag öffnenDupixent · 4.8 · Atopic Hand and Foot Dermatitis The safety of dupilumab was assessed in 27 paediatric patients 12 to 17 years
Eintrag öffnenDupixent · 4.8 · Atopic dermatitis The safety profile of dupilumab + TCS (CHRONOS) in adult atopic dermatitis patients) through
Eintrag öffnenDupixent · 4.8 · Atopic dermatitis The safety profile of dupilumab + TCS (CHRONOS) in adult atopic dermatitis patients) through
Eintrag öffnenDupixent · 4.8 · CRSwNP The safety profile of dupilumab in adults with CRSwNP through week 52 was consistent with the safety pr
Eintrag öffnenDupixent · 4.8 · CRSwNP The safety profile of dupilumab in adults with CRSwNP through week 52 was consistent with the safety pr
Eintrag öffnenDupixent · 4.8 · Children 1 to 11 years of age The safety of dupilumab was assessed in a trial of 101 children 1 to 11 years of
Eintrag öffnenDupixent · 4.8 · Children 1 to 11 years of age The safety of dupilumab was assessed in a trial of 101 children 1 to 11 years of
Eintrag öffnenDupixent · 4.8 · Children 6 months to 5 years of age The safety of dupilumab with concomitant TCS was assessed in a study of 16
Eintrag öffnenDupixent · 4.8 · Children 6 months to 5 years of age The safety of dupilumab with concomitant TCS was assessed in a study of 16
Eintrag öffnenDupixent · 4.8 · Children 6 to 11 years of age The safety of dupilumab was assessed in a study of 367 patients 6 to 11 years of
Eintrag öffnen